We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

39 hedge funds and large institutions have $6.18M invested in Oramed Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

48% more call options, than puts

Call options by funds: $730K | Put options by funds: $493K

23% more capital invested

Capital invested by funds: $5.01M → $6.18M (+$1.18M)

11% more funds holding

Funds holding: 35 → 39 (+4)

2.36% less ownership

Funds ownership: 8.52% → 6.15% (-2.4%)

44% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 9

Holders
39
Holders Change
+4
Holders Change %
+11.43%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
5
Reduced
9
Closed
8
Calls
$730K
Puts
$493K
Net Calls
+$237K
Net Calls Change
+$170K

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$99K
2
LPL Financial
LPL Financial
California
+$46K
3
HighTower Advisors
HighTower Advisors
Illinois
+$43.9K
4
Bank of America
Bank of America
North Carolina
+$41.7K
5
OC
Oppenheimer & Co
New York
+$39K

Top Sellers

Rank Fund Capital Flow
1
PF
Phoenix Financial
Israel
-$483K
2
Renaissance Technologies
Renaissance Technologies
New York
-$313K
3
EMG
ETF Managers Group
New Jersey
-$255K
4
Millennium Management
Millennium Management
New York
-$152K
5
Citadel Advisors
Citadel Advisors
Florida
-$106K
Name Holding Trade Value Shares
Change 		Change in
Stake
JSMC
1
Jess S. Morgan & Co
California
$2.45M +$3.25K +1,000 +0.2%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.58M -$313K -96,200 -21%
FWM
3
Frontier Wealth Management
Missouri
$305K – – –
BlackRock
4
BlackRock
New York
$292K -$66K -20,266 -23%
Qube Research & Technologies (QRT)
5
Qube Research & Technologies (QRT)
United Kingdom
$230K -$68.7K -21,104 -28%
Marshall Wace
6
Marshall Wace
United Kingdom
$155K -$71.6K -22,016 -38%
Squarepoint
7
Squarepoint
New York
$129K +$99K +30,427 New
Millennium Management
8
Millennium Management
New York
$100K -$152K -46,567 -66%
LP
9
LMR Partners
United Kingdom
$98K -$32.2K -9,897 -30%
PNC Financial Services Group
10
PNC Financial Services Group
Pennsylvania
$90K – – –
Jane Street
11
Jane Street
New York
$86K -$40.5K -12,444 -38%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$71K – – –
WG
13
Winton Group
United Kingdom
$69K -$38.9K -11,963 -42%
RPC
14
Rossmore Private Capital
Connecticut
$64K – – –
LPL Financial
15
LPL Financial
California
$60K +$46K +14,135 New
Bank of America
16
Bank of America
North Carolina
$57K +$41.7K +12,821 +1,832%
HighTower Advisors
17
HighTower Advisors
Illinois
$57K +$43.9K +13,500 New
OC
18
Oppenheimer & Co
New York
$51K +$39K +12,000 New
Citigroup
19
Citigroup
New York
$37K – – –
Morgan Stanley
20
Morgan Stanley
New York
$35K +$8.05K +2,475 +43%
CAM
21
Close Asset Management
United Kingdom
$32K – – –
BCM
22
Bourgeon Capital Management
Connecticut
$24K – – –
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$19K +$3.25K +1,000 +29%
Barclays
24
Barclays
United Kingdom
$16K – – –
GWM
25
Geneos Wealth Management
Colorado
$14K +$4.56K +1,400 New
1
2

ORMP Hedge Fund Activity: Q4 2020 in Review

39 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2020, worth a combined $6.18M — up 23% from $5.01M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ORMP positions and 8 closed out — a net gain of 4 holders — while 5 added to existing stakes and 9 trimmed.

The largest buyer was Squarepoint, opening a new position worth an estimated $99K. The largest seller was Phoenix Financial, exiting entirely with an estimated $483K sold.

  • 39 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2020, up from 35 in Q3 2020.
  • Funds reported $6.18M of Oramed Pharmaceuticals stock for Q4 2020, up 23% quarter-over-quarter.
  • 12 funds opened new Oramed Pharmaceuticals positions in Q4 2020 and 8 closed out, a net change of +4 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2020 was Squarepoint, an estimated $99K added.
  • The largest Oramed Pharmaceuticals seller in Q4 2020 was Phoenix Financial, an estimated $483K sold.

Based on aggregated 13F filings for Q4 2020.